South Korea’s HK Inno.N Corp. said on May 2 that it gained exclusive development and commercial rights to Hangzhou, China-based Sciwind Biosciences Co. Ltd.’s once-weekly, injectable glucagon-like peptide-1 (GLP-1) agonist, XW-003 (ecnoglutide), in South Korea to treat type 2 diabetes and obesity.
As Poseida Therapeutics Inc. anticipates reporting further data this year from allogeneic CAR T-cell therapy P-MUC1C-ALLO1, for which Astellas Pharma Inc. has nabbed first negotiation rights, the two companies inked a second deal aimed at combining their respective cell therapy platforms in an early stage collaboration targeting solid tumors.
Novartis Pharma AG continues to build up its radiopharmaceutical powerhouse and has expanded a peptide discovery collaboration with Peptidream Inc. in a deal worth up to $2.71 billion. Under the multi-program agreement, Kawasaki, Japan-based Peptidream will use its peptide discovery platform system technology to identify and optimize novel macrocyclic peptides against targets selected by Novartis for potential conjugation to radioligand therapies or other applications for both therapeutic and diagnostic purposes.
A week after Bristol Myers Squibb Co. disclosed a significant restructuring plan to focus on long-term growth drivers, the big pharma partnered with Repertoire Immune Medicines Inc. in an early stage, multiyear collaboration to develop T-cell targeted medicines for up to three autoimmune diseases, paying $65 million up front, with a potential $1.8 billion in development, regulatory and commercial milestones, along with tiered royalties.
In a $2.4 billion deal, Deciphera Pharmaceuticals Inc. is merging with Ono Pharmaceutical Co. Ltd. Ono is acquiring all of Deciphera’s outstanding stock shares for $25.60 each in cash. The merger helps Osaka, Japan-based Ono strengthen its oncology portfolio and its presence in the U.S.
Antibody-drug conjugates are the hot spot for deals in Asia, but investors questioned whether oncology is really the place to be, during the Asia Bio Partnering Forum in Singapore April 24 to 25.
Seven years after embarking on in vivo therapeutic development using CRISPR/Cas gene-editing technology with Intellia Therapeutics Inc., Regeneron Pharmaceuticals Inc. is bringing another company into the collaborative fold. Regeneron will pay Mammoth Biosciences Inc. $100 million, including $95 million as an equity investment, and an up-front payment. Mammoth also could bring in up to $370 million for each target in milestones along with royalties on net sales from products created through the collaboration.
With a frozen IPO market, investors are tightening their belts and figuring out where to hedge their bets. In Asia, that means having different strategies for different countries while keeping a global mindset, venture capital (VC) investors said during the Asia Bio Partnering Forum in Singapore on April 25.
Big pharma continues to seek innovation in China despite rising geopolitical tension, speakers said at the Asia Bio Partnering Forum in Singapore April 24.
Vertex Pharmaceuticals Inc. has tapped into Treefrog Therapeutics SA’s high-throughput stem cell manufacturing technology in a deal worth potentially up to $780 million to help it advance its type 1 diabetes programs, including phase I/II asset VX-880.
RSS
